53220KAF5
Ligand Pharmaceuticals Incorporated
Could not find a ticker for this position, may be a filing error
A biopharmaceutical company that licenses drug technologies and collects royalties on medicines its partners develop and sell. Its best-known asset is Captisol, a sugar-based "cage" that wraps around hard-to-dissolve drugs to make them stable and deliverable. Founded in 1987 as Progenx, Inc., it was renamed Ligand Pharmaceuticals in 1989 after the biochemistry term for a molecule that binds to a receptor — a nod to its original focus on receptor biology.
CONVERTIBLEUnderlying: LGNDCUSIP: 53220KAF5HealthcareUS1 derivative reporter
0.75% Convertible Senior Notes due 2023
No tracked superinvestor held this security as stock in this period — only the derivative positions below reference it.
Derivative Reporters
Investor
Kind
13F reported value
Quantity
Change
